Objective. Health care providers are likely to see an increase in the concomitant use of cannabis and opioids, particularly with the increased liberalization and ongoing research into the possible role of medical marijuana for chronic pain. Recent literature reports a prevalence of concurrent use ranging from 8.9% to 31.8%. The primary aim of this study was to determine the relationship between cannabis use and aberrant drug behaviors in noncancer pain patients receiving chronic opioid therapy.
Introduction
Cannabis (marijuana) is classified by the United States Drug Enforcement Agency as a Schedule I drug, the category of drugs that have been deemed "most dangerous" by authorities [1] , although current research suggests the potential for benefit in the treatment of certain chronic pain conditions [2, 3] . The evidence basis V C 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com appears to be strongest for neuropathic pain-although problems with cognitive side effects have generally been noted in these randomized controlled trials [4] [5] [6] [7] . At the state level, legislative public policies for comprehensive "medical marijuana" programs exist in 28 states, the District of Columbia, Guam, and Puerto Rico [8, 9] . Reflective of these changes, data derived from the National Epidemiologic Survey on Alcohol and Related Conditions revealed that cannabis use has doubled between 2001 and 2013 [10] . Additionally, the strength of the cannabis (as measured by D9-tetrahydrocannabinol [THC] levels) has increased dramatically [11] . Concurrently, an increase in adverse consequences of cannabis use has been observed during a similar time period in the general population, including the 12-month prevalence of cannabis use disorder rising from 1.5% in 2001 to 2.9% in 2013 as defined by the Diagnostic and Statistical Manual of Mental Disorders Fourth EditionRevised, illicit drug-related emergency department visits involving cannabis rising from 28 .4% in 2004 to 38 .3% in 2011, and fatal car accidents with cannabis-positive toxicology results rising from 4.2% in 1999 to 12.2% in 2010 [10, 12, 13] . The controversy persists, particularly with recent data showing that medical marijuana laws may mitigate rates of opioid overdose deaths [14, 15] and that many patients with pain are substituting cannabis for opioids in order to achieve analgesia [16] . Emerging evidence of a degree of efficacy in conjunction with data illustrating safety issues and the prevalence of adverse events underscores the importance of more carefully assessing the risk factors associated with concurrent marijuana use and chronic opioid therapy.
Cannabis use in patients receiving chronic opioid therapy has also been well documented, with several studies demonstrating cannabis to be the most common illicit drug detected by urine drug toxicology (UDT) [17] [18] [19] [20] [21] . Unfortunately, few published studies have examined the possible risks associated with cannabis use in patients receiving chronic opioid therapy. In a prospective cohort study, Ives and colleagues reported that cannabis use was associated with opioid misuse in patients receiving chronic opioid therapy [22] . However, the results from this study may not generalize to the chronic pain population as recruitment efforts focused on subjects already suspected of opioid misuse. Reflective of their study population's risk for substance misuse, the authors also reported high rates of preexisting substance abuse disorders (29% with a history of cocaine abuse and 28% with a history of alcohol abuse) and prior drug and/or alcohol conviction(s) (20%). Fleming and colleagues administered standardized questionnaires and urine drug testing to 801 adult subjects receiving daily opioid treatment to determine the relationship between UDT results, aberrant drug behaviors (ADBs), and the prevalence of both current general substance use and more specifically opioid use disorders (within the previous 30 days, as defined by accepted diagnostic criteria) [23] . They found that, while UDTs positive for cannabis were associated with general substance use disorders, the use of cannabis did not predict the presence of an opioid use disorder.
With the progressive liberalization of medical and recreational laws and the number of patients currently being prescribed chronic opioids, health care providers are likely to see an increase in the concomitant use of cannabis and opioids. As such, the primary aim of this study was to determine the relationship between cannabis use and the occurrence of subsequent ADBs in noncancer pain patients receiving chronic opioid treatment in a community-based, interdisciplinary treatment setting. Secondary study goals were to explore the qualitative and quantitative differences in ADBs between cannabis and noncannabis users and the relationships between other potentially predictive factors (demographic variables, intensity of treatment, results from standardized risk and functional assessment tools, initial morphine equivalent dose) and the occurrence of ADBs.
Methods
A retrospective medical record review was conducted to examine the relationship between cannabis use and the occurrence of ADBs among patients receiving chronic opioid medication for persistent pain. The Tufts University Institutional Review Board reviewed this study prior to initiating any study activities.
Subjects
Eligible subjects included 588 patients who were evaluated for a medication management program between October 1, 2011, and January 1, 2014, inclusive, at one community-based, interdisciplinary pain management center and who met all of the following criteria: The subject provided at least one urine sample for UDT prior to the evaluation for the medication management program, completed enrollment into the program, and received at least one prescription for a daily dose of opioid medication within 12 weeks following the evaluation visit. Subjects were assigned to the THC-positive group (N ¼ 44) or THC-negative group (N ¼ 544) determined by the presence or absence of THC in the initial UDT, respectively. One hundred sixty-five of the 544 assigned to THC-negative group were randomly selected to represent the THC-negative group in data analysis. This sample of 209 subjects included in data analysis was determined to be adequate to obtain a type I error rate of 5% and a power of 80%, using nQuery Advisor (version 7.0) based on published aberrancy rates [22] .
The medication management program utilizes a number of opioid risk assessment tools as standard practice, including self-report questionnaires, information from the prescription monitoring program, collateral phone calls to psychiatric providers and primary care providers, UDT results, and interdisciplinary clinical interview evaluations. An interdisciplinary clinical team reviews all the information to determine the degree of opioid-related risks and the patient's initial plan of care. Patients using cannabis are informed at the outset that they will not be enrolled into the medication management program unless they choose to discontinue cannabis. Once enrolled into the medication management program, aberrancies are addressed in a number of ways, often first by increasing the level of monitoring of opioid use and involving a behavioral medicine specialist to assess risk factors and provide additional treatment. Immediate discharge occurs when there is evidence of illegal behavior or active addiction.
Demographic Variables
Age at the time of evaluation for chronic opioid medication, sex, marital status, and smoking status were collected for each subject.
Aberrant Drug Behaviors
Aberrant drug behaviors such as dose escalation, altering the route of administration of the opioid, or filling overlapping prescriptions from multiple prescribers are behaviors suggestive of opioid misuse, and possibly another substance use disorder [24] . UDT was used as an objective measure of ADBs. Inconsistent UDT data can suggest one of many concerning ADBs (i.e., dose escalation, use of illicit substances) but do not capture all types (i.e., multiple prescriptions).
An inconsistent UDT result was defined as
• the presence of an opioid medication not currently prescribed by the pain management center; • the absence of a prescribed opioid medication; or • the presence of an illicit substance (including cannabis) or alcohol.
Urine samples were analyzed using immunoassays (Table 1 ) and further analyzed using gas chromatography/mass spectrometry when the presumptive result of the immunoassay was inconsistent. A monoclonal antibody assay capable of detecting the major metabolite of D 9 -THC was used for the qualitative and semiquantitative measurements of cannabinoids in human urine. Measurements of creatinine, specific gravity, general oxidants and pH, and temperature were completed for confirmation of specimen validity.
A UDT was obtained from each patient at the time of referral for the medication management program. All patients are made aware of the clinic's policy to obtain UDTs at each opioid prescribing visit. Qualitative descriptions regarding inconsistent UDTs (e.g., positive cocaine, negative prescribed medication) were gathered from the medical record.
Questionnaires
The Current Opioid Misuse Measure (COMM) is a 17-item self-report measure assessing behaviors of patients on chronic opioid therapy with good reliability and validity reported in previous studies [25, 26] . A cutoff score of 9 is used to indicate higher risk of opioid misuse and ADBs.
The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a 24-item self-report measure designed to predict opioid misuse in patients with chronic pain for whom initiation of chronic opioid therapy is being considered [27] [28] [29] . A cutoff score of 18 or greater is used to indicate higher risk of opioid misuse and ADBs.
The Oswestry Disability Index (ODI) [30, 31] was administered as standard of care until November 2013, at which time a modified version of the Roland Morris Disability Questionnaire (RMDQ) [32] was administered to assess disability due to pain. While both the ODI and RMDQ are specific to back pain, the items on the modified RMDQ were made more general to any pain condition (e.g., "I walk more slowly than usual because of my back" to "I walk more slowly than usual because of my pain"). Similar modifications to the items have been described in the literature and supported by the authors of the RMDQ [33, 34] .
Pain Severity
Pain severity rating at the time of evaluation for the medication management program and at last visit within 12 months of enrollment was reported as a whole number using an 11-point numerical rating scale, with anchors of 0 representing "no pain" and 10 representing the "worst imaginable pain."
Opioid Medication Dose
Daily opioid dose at the time of enrollment into the medication management program and at last visit within 12 months of enrollment was collected from the medical record, as well as the route of administration (oral, transdermal, or combination). Opioid dose was calculated as milligrams morphine equivalent using the calculator developed and published by the Washington State Agency Medical Directors' Group [35] . While there are differences among opioids (and most concerningly with methadone) that are not accurately captured in using a conversion formula for morphine equivalent dose (MED) [36, 37] , there remains clinical utility in using MED when managing patients on chronic opioid therapy, including the avoidance of unwanted dose escalations that can frequently occur during long-term opioid treatment [8, 39] .
Medication Management Program Status
Frequency of prescribing visits (monthly, biweekly, or weekly visits) at the time of enrollment into the medication management program was collected from the record. This was decided by the clinical team based on the assessed level of risk for opioid misuse following a review of evaluation data. Status in the medication management program at the final visit within the study period (active, discharged by the center, or inactive by patient choice) and the reasons for discharge from the program were collected from the medical record.
Statistical Analysis
First, descriptive statistics were computed. To address the primary goal of determining the relationship between cannabis use and subsequent ADBs, a Pearson chisquare test was used for the categorical variables of THC group status and UDTs being either entirely consistent or at least one inconsistent during the study period. The relationships between other potentially predictive factors (demographic variables, intensity of treatment, results from standardized risk and functional assessment tools, initial morphine equivalent dose) and the occurrence of ADBs were assessed using Pearson chi-square tests and Fisher's exact tests in lieu of Pearson chi-square tests in cases of sparse expected cell counts. Mann-Whitney U tests were used for continuous outcomes, all of which were non-normally distributed. Differences in the types of ADBs between cannabis and noncannabis users were categorized using qualitative data, and rates of occurrence of each category were calculated for THC-positive and THCnegative groups. In the final stage of analysis, associations between variables were studied using generalized estimating equations (GEE), a statistical method that accounts for the fact that different subjects had different numbers of urine samples analyzed during the study period. A P value of less than 0.05 was considered statistically significant. SAS 9.4 was used for GEE, and SPSS Version 22 was used for all other analyses.
Results
Statistically significant differences were found between the THC-positive and THC-negative groups on only three of the 14 demographic and medical variables ( Table 2 ). The THC-positive group was comprised of a significantly larger proportion of males (65.9%) than the THC-negative group (49.1%, P ¼ 0.047) and a larger proportion of subjects endorsing a history of substance use disorder (36.4%) than the THC-negative group (18.8%, P ¼ 0.013). Subjects in the THC-positive group were less likely to be enrolled in the medication management program with the lowest level of monitoring (22.7%) than subjects in the THC-negative group (47.3%, P ¼ 0.008).
Use of THC and Aberrant Drug Behaviors
Ninety-six (45.9%) of the 209 subjects included in the data analysis produced one or more inconsistent UDTs during the study period. The group of subjects with one or more inconsistent UDTs was comprised of a significantly larger proportion of subjects in the THC-positive group (35.4%) than the group with entirely consistent UDTs (8.8%, P < 0.001). A greater proportion of those with entirely consistent UDTs during the study (49.6%) were placed into the lowest level of monitoring for opioid medications upon enrollment into the medication management program than those with one or more inconsistent UDTs (33.3%, P ¼ 0.035). There were no statistically significant differences for all other variables ( Table 3 ). The groups were further analyzed using generalized estimating equations (GEE) to account for some subjects producing more UDT samples than others during the study period. The 209 subjects produced a total of 2,627 urine samples during the study period, with 240 (9.1%) determined to be inconsistent UDTs, indicating aberrant behavior. Having a status of being assigned to the THC-positive group was associated with increased occurrence of inconsistent UDTs (OR ¼ 7.26, 95% CI ¼ 4.49-11.75, P < 0.001).
Data were also analyzed with a recoding of THC use so that the presence of THC in the UDT was not considered an ADB. For example, if a UDT was inconsistent due to positive THC and negative prescribed opioid, it remained coded inconsistent. If an inconsistent UDT was due to the presence of THC without other inconsistencies, it was coded as consistent. This recoding of inconsistent UDTs resulted in a reduction of those in the THC-positive group with one or more inconsistent UDTs during the study period (N ¼ 21) and no changes to those in the THC-negative group with one or more inconsistent UDTs (N ¼ 62). Although the chi-square test was not significant (P ¼ 0.221), the GEE was significant (OR ¼ 2.50, 95% CI ¼ 1.49-4.20, P < 0.001), indicating that subjects in the THC-positive group had a greater proportion of inconsistent findings on UDTs.
Qualitative Examination of ADBs
Qualitative analysis of inconsistent UDT data indicated differing patterns of aberrancies between the THC-positive group and the THC-negative group (Table 4) . Of the 240 inconsistent UDTs during the study period, the THC-positive group produced 130, while the THC-negative group produced 110. Cannabis use was more common among inconsistent UDTs for the THC-positive group (58.5%) than the THCnegative group (5.5%). The use of alcohol was present in UDTs only among the THC-negative group (5.5%). Taking a nonprescribed medication and testing negative for a prescribed medication occurred more frequently among the THC-negative group. A greater 
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proportion of subjects in the THC-positive group (43.2%) than the THC-negative group (20.0%) were discharged from the medication management program at the end of the study period (Table 5 ). Only subjects in the THC-positive group were discharged for the reason of ongoing cannabis use.
Discussion
This retrospective cohort study demonstrates that cannabis use is associated with the occurrence of aberrant drug behaviors in patients receiving chronic opioid therapy. As hypothesized, the presence of cannabis in a subject's initial urine sample predicted the occurrence of future ADBs as compared with subjects in the THCnegative group. This relationship remained significant irrespective of whether continued use of cannabis was considered an aberrant behavior.
The predictive relationship between cannabis use and ADBs is consistent with and expands upon the extant literature [22, 23] . Similar to previously published data [17, 20, [40] [41] [42] , cannabis was the most common nonopioid substance detected in the UDTs of subjects in our study (detected in 7.48% of all initial samples). In contrast to earlier studies, the overall rate of aberrant UDT results observed in this study (9.1%) was lower than those reported in published literature [42] [43] [44] [45] . Our results also differ from previous studies [46, 47] in that we found no statistically significant relationship between an individual's history of substance abuse or daily morphine equivalent dose and the occurrence of ADBs.
The divergence of our findings from previously published data may be related to differences in study populations and treatment approaches. Unlike previous studies that examined pain subgroup populations (e.g., patients suspected of significant opioid misuse [22] ), candidates for inclusion in our study were randomly selected without regard for medical diagnosis, demographics, or past medical history. As a result, our sample may be more representative of the typical population of chronic pain patients presenting for opioid treatment. Results from behavioral and functional evaluations factor heavily in team decisions regarding treatment selection and intensity. Patients considered at increased risk for ADBs are provided with highly structured care plans involving more frequent clinic visits, drug testing, and use of behavioral health interventions (educational workshops, motivational interviewing, mindfulness training, cognitive behavioral therapy, and acceptance/commitment therapy) that may reduce the occurrence of ADBs [48, 49] .
The interdisciplinary assessment process may also select out individuals at the highest risk for ADBs as opioid treatment is avoided when the risk for misuse is considered to be high (e.g., active substance use disorder) or when the likelihood of achieving a meaningful treatment response is considered low (e.g., presence of significant catastrophization, diagnosis of a somatic symptom disorder, or an inability to identify functionally oriented treatment goals).
Despite their limitations, risk stratification tools (SOAPP-R, COMM) have been validated in the chronic pain population [26, 29, [50] [51] [52] and are frequently utilized when performing opioid misuse risk assessments. However, in our study population, the determination of risk derived from these tools was neither predictive of future ADBs nor sensitive to differences between the two study groups. Exclusion of high-risk patients from the clinic's medication management program also may account for differing results as our study included only those who were ultimately enrolled and prescribed chronic opioid therapy. Validity of risk assessment questionnaires can also be undermined by response bias. Patients who are highly motivated to receive opioid medications may provide untruthful responses in an attempt to lower perceptions of risk for substance misuse. Butler and colleagues attempted to address the possibility of response bias in their validation work for the SOAPP-R through co-administration with the Marlowe-Crown Social Desirability Scale [28] . Their findings suggested that data derived from the SOAPP-R are not purely measures of social desirability and that subjects displayed an overall willingness to self-disclose. However, validation study subjects were assured that study information would not be incorporated into their clinical records nor have any impact on their clinical treatment. In contrast, decisions regarding opioid treatment are influenced by questionnaire results when used during the performance of risk assessments, and thus introduce additional motivation for misrepresentation beyond issues of social desirability.
Although several studies have demonstrated a relationship between cannabis use and ADBs in patients receiving opioid treatment [18, 22, 23, 53] , outcomes have predominantly focused on the analysis of UDT data. While UDT data were examined in our study, we also explored differences in the occurrence of ADBs identified through means other than UDT, as well as the specific reasons for treatment discharge. Discontinuation of opioid treatment for reasons unrelated to UDT-identified aberrancies (e.g., non-UDT-related violations of the program agreement, lack of functional improvement, and newly developed medical complexity) was observed during our study. Nonetheless, inconsistent UDTs remained the most common reason for discharge in both groups (Table 5) . One explanation for these results may be the treatment team's predisposition toward attempts to curtail aberrant behaviors by using available interdisciplinary interventions (i.e., behavioral health services, functional services, increased levels of monitoring) rather than discharge when confronted with aberrancies identified by means other than UDT. The majority of discharges occurring as a result of UDT inconsistencies may also be reflective of urine drug testing's superiority in detecting aberrant behaviors, with research data indicating the failure of behavioral observation and screening to identify almost half of all patients at high risk for aberrant behaviors [21] .
Qualitative results from our study revealed differing patterns of inconsistent UDTs, with continued cannabis use more common in the THC-positive group (58.5%) than in the THC-negative group (5.5%), while alcohol use was present only in the THC-negative group (N ¼ 6, 5.5%). Although the use of cannabis or alcohol differed between our two study groups, patient motivations for using these substances may be similar. Studies have demonstrated that as many as 28% of people with chronic pain use alcohol for the purpose of pain management [54, 55] . Although studies indicate that alcohol has some analgesic properties, pain-reducing effects occur at doses exceeding the guidelines for moderate daily alcohol use [56] . An analgesic effect in alcohol users is suggested by several studies examining the relationship between the expectancies surrounding the use of alcohol and pain perception. Cutter et al. [57] demonstrated pain reduction with the consumption of alcohol only in subjects who reported drinking to forget their problems. In another study, modulation in pain perception was observed in subjects who reported emotional benefit from alcohol when told they had received alcohol (reduced pain) or tonic (increased pain) [58] . Similarly, positively held beliefs regarding cannabis may influence a patient's perception of treatment benefit and increase the likelihood of its use.
Another finding in the qualitative data is that inconsistencies in UDTs related to opioids occurred more frequently among the THC-negative group (Table 4) .
Taking a nonprescribed medication occurred in 30.0% of inconsistent UDT samples in this group compared with 11.5% of inconsistent UDTs in the THC-positive group, and testing negative for a prescribed medication occurred in 57.3% of inconsistent UDTs in the THCnegative group compared with only 29.2% of inconsistent UDTs in the THC-positive group. This difference between groups might indicate consistency with other published data that patients with pain are substituting cannabis for opioids in order to achieve analgesia [2, 3, 14, 16] and thereby not using opioids from old prescriptions, borrowing nonprescribed opioids from others, or escalating their dose and running out early. However, the absence of the prescribed opioid in a urine sample could also indicate issues of diversion or other types of aberrant behaviors that are not related to the level of analgesia a patient is experiencing.
Medical marijuana has been presented as an alternative or adjunctive treatment to opioids [59] , and recent studies have shown promise with particular pain conditions [2, 3] . Even if it is ultimately determined that cannabis has risk mitigation or opioid-sparing properties, future positive findings would not diminish the importance of examining the full range of risk factors in any patient using controlled substances. The data from our study and others [18, 53] suggest that the concurrent use of cannabis and opioids may be associated with the misuse of opioid medications.
Subjects in the present study were not using cannabis under medical supervision, and therefore concerns are raised regarding whether similar misuse patterns are observed in patients utilizing medical cannabis. Published descriptive data on a sample of 348 adults seeking medical cannabis at a certification clinic in Michigan [60] found that the majority were doing so for pain relief (87%). Prescription opioid misuse was common, with 40% reporting nonprescribed opioid use at some point in their lifetime, while 20% reported nonprescribed use within the prior three months. Recent nonopioid substance use was also significant, with 13% reporting potentially problematic alcohol use, 9% nonprescribed sedative use, 6% hallucinogen use, and 3% cocaine and amphetamine use within the preceding three months. Ninety-three percent of first-time visitors reported having used cannabis at some time in their lives, while 61% reported daily or almost daily use within the three months prior to the interview. These findings suggest that patients presenting for medical cannabis treatment may share similar risks for ADBs as those self-medicating with cannabis presenting for opioid treatment.
Although the present study demonstrates a relationship between cannabis use and ADBs in patients receiving chronic opioid therapy, our findings should be interpreted with caution. This study was conducted in Massachusetts, where the use of cannabis for medicinal purposes was legalized during the study inclusion period in 2012; however, no subjects enrolled in this study DiBenedetto et al.
were identified as medical cannabis users. As such, no inferences can be extrapolated to this patient population from our data. Additionally, subjects in this study were receiving treatment in a multispecialty clinic in which information obtained from comprehensive behavioral and functional assessments guides decisions regarding opioid treatment. Conclusions reached in this study may therefore not be generalizable to patients receiving opioid treatment in a primary care or single discipline setting as our assessment process may eliminate patients who would otherwise receive such treatment elsewhere.
The accuracy of study results may also be negatively influenced by the introduction of biases inherent in retrospective cohort study designs. For example, patients enrolled in the medication management program are informed of the clinic's policy regarding the prohibition of cannabis use with opioid treatment. As such, population selection bias therefore may be introduced by the elimination of patients who remain at the center and elect to forego opioid treatment in favor of cannabis use and those who choose to seek pain treatment elsewhere at a facility that allows concurrent cannabis and opioid use. Finally, the potential for selection bias manifested as early discharge from the program should be considered as clinicians may choose to discharge patients considered "substance abusers" prematurely [61] .
Conclusion
Concurrent use of cannabis and opioids by patients with chronic pain appears to indicate higher risk for opioid misuse. Our results demonstrate that cannabis use is predictive for the occurrence of aberrant drug behaviors in patients receiving chronic opioid treatment. Continued cannabis use was the most common aberrancy observed among patients using cannabis at the time of their initial assessment. Furthermore, cannabis use remained predictive of ADBs in an additional analysis when continued use of cannabis was recoded and not considered an ADB. Review of published descriptive data suggests similar risk for ADBs in patients seeking cannabis treatment for pain relief. As such, the use of medical cannabis treatment agreements as recommended by Wilsey and colleagues [62] and interdisciplinary interventions similar to those recommended in the management of chronic opioid therapy should be considered in patients presenting for medical cannabis treatment. Cannabis disorder-specific screening instruments may be more sensitive than opioid risk assessment tools and also should be considered when evaluating patients for medical cannabis treatment and in cannabis users presenting for opioid treatment [63] .
The data from this and similar studies suggest an important role for comprehensive assessment and management of the chronic pain patient, particularly as cannabis use becomes more prevalent for both medical and recreational usage. Liberalization of marijuana laws appears to increase overall usage, with medical marijuana laws associated with increased overall use among adults and increased use initiation among adolescents and young adults [64] , and legalization of recreational use likely to result in an increase in overall use in the long term [65] . Additional prospective data, preferably derived from a multicenter trial spanning varying treatment environments (specialty pain care vs primary care, interdisciplinary vs single specialty), are needed to better define the risks, predictive factors, and effective treatment interventions in this subgroup of the overall pain patient population.
